Carglumic acid

Carglumic acid

Systematic (IUPAC) name
(2S)-2-(carbamoylamino)pentanedioic acid
Clinical data
AHFS/Drugs.com	Consumer Drug Information
Licence data	EMA:Link
Pregnancy category	unknown
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	30%
Protein binding	Undetermined
Metabolism	Partial
Biological half-life	4.3 to 9.5 hours
Excretion	Fecal (60%) and renal (9%, unchanged)
Identifiers
CAS Number	1188-38-1
ATC code	A16AA05
PubChem	CID 121396
IUPHAR/BPS	7458
DrugBank	DB06775
ChemSpider	1265942 108351
UNII	5L0HB4V1EW
KEGG	D07130
ChEBI	CHEBI:71028
ChEMBL	CHEMBL1201780
Synonyms	(S)-2-ureidopentanedioic acid
Chemical data
Formula	C6H10N2O5
Molar mass	190.2 g/mol
SMILES C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N
InChI InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1 Key:LCQLHJZYVOQKHU-VKHMYHEASA-N
(what is this?)  (verify)

Carglumic acid is an orphan drug, marketed by Orphan Europe under the trade name Carbaglu. Carglumic acid is used for the treatment of hyperammonaemia in patients with N-acetylglutamate synthase deficiency.^[1][2] The initial daily dose ranges from 100 to 250 mg/kg, adjusted thereafter to maintain normal plasma levels of ammonia.

The US FDA approved it for treatment of hyperammonaemia on March 18, 2010. Orphan Drug exclusivity expires on March 18,2017.^[3]

References

1. Caldovic L, Morizono H, Daikhin Y, Nissim I, McCarter RJ, Yudkoff M, Tuchman M (2004). "Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate". J Pediatr 145 (4): 552–4. doi:10.1016/j.jpeds.2004.06.047. PMID 15480384.
2. Elpeleg O, Shaag A, Ben-Shalom E, Schmid T, Bachmann C (2002). "N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy". Ann Neurol 52 (6): 845–9. doi:10.1002/ana.10406. PMID 12447942.
3. "Patent and Exclusivity Search Results".